ARVN - Latest News
Arvinas, Inc. (ARVN), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $440.0M. Trailing twelve-month P/E ratio is 47.52. Beta to the broader market is 1.81.
The article list below shows the most recent ARVN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ARVN Headlines
Reasons Why Investors Should Consider Betting on Arvinas Stock
zacks.com - Oct 13, 2026
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers furthe
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
globenewswire.com - Oct 7, 2026
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®
globenewswire.com - Oct 1, 2026
NEW HAVEN, Conn. , Oct.
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Sep 29, 2026
NEW HAVEN, Conn. , Sept.
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
globenewswire.com - Sep 28, 2026
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –
How News Affects ARVN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ARVN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ARVN news questions
- What is the latest ARVN news headline?
- The most recent ARVN headline (Oct 13, 2026) is "Reasons Why Investors Should Consider Betting on Arvinas Stock". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ARVN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ARVN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ARVN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.